As the field of gene therapy has developed, applications to treatment of infectious diseases, such as HIV-1 infection, have been explored. The hematopoietic stem cells (HSC) contained in either bone marrow or the umbilical cord blood from newborns represent a logical target cell for gene therapy of AIDS. HSC produce the full spectrum of cells involved in AIDS pathogenesis: T lymphocytes, monocytes, macrophages, dendritic cells, and microglial (17,18). HSC are long-lived, producing new progeny cells for the life of the recipient after transplant. Therefore, insertion of a gene capable of conferring resistance to HIV-1 into hematopoietic stem cells could result in that gene being present in the mature T lymphocytes and other HIV-1-susceptible cells which are produced. Recent incremental improvements in Moloney murine leukemia virus (MLV) retroviral-mediated gene transfer into human hematopoietic stem cells (HSC) have been achieved (e.g. 10%, up from the previous ceiling of 0.1- 1.0%). However, even higher levels of gene transduction of stem cells are likely to be needed for applications to AIDS. Lentiviral vectors hold the promise of producing increased transduction of HSC, due to their ability to transduce quiescent cells. For anti-HIV-1 genes, the requisite expression parameters will vary, based on specific aspects of the anti- HIV-1 gene product (e.g. active as RNA or translated into protein). To improve methodologies for gene therapy of HIV-1 using hematopoietic stem cells, this project (#1) will be highly interactive with the other Projects and Cores. We will work with Dr. Yee to evaluate the efficacy of novel lentiviral vectors for gene delivery to primitive human hematopoietic progenitor and stem cells. We will work with Dr. Rossi to evaluate gene expression and HIV-1 inhibition by novel expression cassettes for anti-HIV-1 genes. We will also continue to translate the findings form these basic projects into clinical trials, both with preclinical studies as well as with performing the stem cell transductions for clinical trials. These studies will contribute to fundamental advances in the techniques for gene delivery and expression and to their evaluation in subjects with HIV-1 infection.
| Saetrom, Pål; Biesinger, Jacob; Li, Sierra M et al. (2009) A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. Cancer Res 69:7459-65 |
| Kowolik, Claudia M; Yam, Priscilla; Yu, Ying et al. (2003) HIV vector production mediated by Rev protein transduction. Mol Ther 8:324-31 |
| Li, Ming-Jie; Bauer, Gerhard; Michienzi, Alessandro et al. (2003) Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol Ther 8:196-206 |
| Paul, Cynthia P; Good, Paul D; Li, Shirley X L et al. (2003) Localized expression of small RNA inhibitors in human cells. Mol Ther 7:237-47 |
| Michienzi, Alessandro; Li, Shirley; Zaia, John A et al. (2002) A nucleolar TAR decoy inhibitor of HIV-1 replication. Proc Natl Acad Sci U S A 99:14047-52 |
| Chang, Zongli; Westaway, Shawn; Li, Shirley et al. (2002) Enhanced expression and HIV-1 inhibition of chimeric tRNA(Lys3)-ribozymes under dual U6 snRNA and tRNA promoters. Mol Ther 6:481-9 |
| Strayer, David; Branco, Francisco; Zern, Mark A et al. (2002) Durability of transgene expression and vector integration: recombinant SV40-derived gene therapy vectors. Mol Ther 6:227-37 |
| Lee, Nan Sook; Dohjima, Taikoh; Bauer, Gerhard et al. (2002) Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol 20:500-5 |
| Yam, Priscilla Y; Li, Shulian; Wu, Jerry et al. (2002) Design of HIV vectors for efficient gene delivery into human hematopoietic cells. Mol Ther 5:479-84 |
| Michienzi, A; Rossi, J J (2001) Intracellular applications of ribozymes. Methods Enzymol 341:581-96 |
Showing the most recent 10 out of 12 publications
